CN111567804A - 茉莉花咀嚼片及其制备方法 - Google Patents
茉莉花咀嚼片及其制备方法 Download PDFInfo
- Publication number
- CN111567804A CN111567804A CN202010468362.9A CN202010468362A CN111567804A CN 111567804 A CN111567804 A CN 111567804A CN 202010468362 A CN202010468362 A CN 202010468362A CN 111567804 A CN111567804 A CN 111567804A
- Authority
- CN
- China
- Prior art keywords
- jasmine
- percent
- chewable tablet
- magnolol
- tea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000010254 Jasminum officinale Nutrition 0.000 title claims abstract description 110
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 56
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 52
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 240000005385 Jasminum sambac Species 0.000 title description 86
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 claims abstract description 60
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 51
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 40
- 239000000463 material Substances 0.000 claims abstract description 34
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 28
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 20
- 229930195725 Mannitol Natural products 0.000 claims abstract description 20
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 20
- 239000000594 mannitol Substances 0.000 claims abstract description 20
- 235000010355 mannitol Nutrition 0.000 claims abstract description 20
- 235000000346 sugar Nutrition 0.000 claims abstract description 19
- 108010011485 Aspartame Proteins 0.000 claims abstract description 18
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 18
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 18
- 239000000605 aspartame Substances 0.000 claims abstract description 18
- 235000010357 aspartame Nutrition 0.000 claims abstract description 18
- 229960003438 aspartame Drugs 0.000 claims abstract description 18
- 239000008101 lactose Substances 0.000 claims abstract description 18
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 17
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 17
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 17
- 235000006533 astragalus Nutrition 0.000 claims abstract description 17
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 14
- 241000045403 Astragalus propinquus Species 0.000 claims abstract description 9
- 241000207840 Jasminum Species 0.000 claims abstract 25
- 244000269722 Thea sinensis Species 0.000 claims abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 41
- 239000000843 powder Substances 0.000 claims description 36
- 238000000605 extraction Methods 0.000 claims description 28
- 241001673966 Magnolia officinalis Species 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 21
- 239000000706 filtrate Substances 0.000 claims description 20
- 239000003208 petroleum Substances 0.000 claims description 20
- 241000245665 Taraxacum Species 0.000 claims description 18
- 238000007873 sieving Methods 0.000 claims description 17
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
- 241000628997 Flos Species 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- 239000002245 particle Substances 0.000 claims description 15
- 238000005406 washing Methods 0.000 claims description 14
- 239000009636 Huang Qi Substances 0.000 claims description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 12
- 239000008187 granular material Substances 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007779 soft material Substances 0.000 claims description 11
- 238000000194 supercritical-fluid extraction Methods 0.000 claims description 11
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 claims description 10
- 238000001914 filtration Methods 0.000 claims description 10
- 239000011259 mixed solution Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 9
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 8
- 241001061264 Astragalus Species 0.000 claims description 8
- 239000000469 ethanolic extract Substances 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 210000004233 talus Anatomy 0.000 claims description 8
- 235000015165 citric acid Nutrition 0.000 claims description 7
- 238000003825 pressing Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 229940107666 astragalus root Drugs 0.000 claims description 5
- 238000004140 cleaning Methods 0.000 claims description 5
- 239000013078 crystal Substances 0.000 claims description 5
- 238000005520 cutting process Methods 0.000 claims description 5
- 239000008367 deionised water Substances 0.000 claims description 5
- 229910021641 deionized water Inorganic materials 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 238000007605 air drying Methods 0.000 claims description 4
- 239000012530 fluid Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 34
- 230000036039 immunity Effects 0.000 abstract description 12
- 235000019640 taste Nutrition 0.000 abstract description 10
- 206010028980 Neoplasm Diseases 0.000 abstract description 9
- 230000002708 enhancing effect Effects 0.000 abstract description 9
- 241000894006 Bacteria Species 0.000 abstract description 7
- 239000000796 flavoring agent Substances 0.000 abstract description 7
- 231100000331 toxic Toxicity 0.000 abstract description 7
- 230000002588 toxic effect Effects 0.000 abstract description 7
- 239000003205 fragrance Substances 0.000 abstract description 6
- 241000700605 Viruses Species 0.000 abstract description 5
- 238000000034 method Methods 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 4
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 208000026106 cerebrovascular disease Diseases 0.000 abstract description 3
- 235000019634 flavors Nutrition 0.000 abstract description 3
- 238000009776 industrial production Methods 0.000 abstract description 2
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 241001122767 Theaceae Species 0.000 description 39
- 239000003826 tablet Substances 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 239000003814 drug Substances 0.000 description 10
- 150000004676 glycans Chemical class 0.000 description 10
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 230000001603 reducing effect Effects 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 238000001291 vacuum drying Methods 0.000 description 9
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 210000004185 liver Anatomy 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 240000000851 Vaccinium corymbosum Species 0.000 description 5
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 5
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 5
- 240000003248 Zanthoxylum nitidum Species 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 235000021014 blueberries Nutrition 0.000 description 5
- 230000000857 drug effect Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 201000007270 liver cancer Diseases 0.000 description 5
- 208000014018 liver neoplasm Diseases 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- 238000004659 sterilization and disinfection Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 229930194248 Licoflavone Natural products 0.000 description 4
- MEHHCBRCXIDGKZ-UHFFFAOYSA-N Licoflavone C Natural products CC(C)=CCC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=C(O)C=C1 MEHHCBRCXIDGKZ-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000214 mouth Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 101150107278 POLD1 gene Proteins 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BAHMQESJBKGPTE-UHFFFAOYSA-N 1,5,8-trimethyl-3a,4-dihydroazuleno[6,5-b]furan-2,6-dione Chemical compound C1C2OC(=O)C(C)=C2C=C2C(C)=CC(=O)C2=C1C BAHMQESJBKGPTE-UHFFFAOYSA-N 0.000 description 2
- 206010000087 Abdominal pain upper Diseases 0.000 description 2
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- BTJXBZZBBNNTOV-UHFFFAOYSA-N Linalyl benzoate Chemical compound CC(C)=CCCC(C)(C=C)OC(=O)C1=CC=CC=C1 BTJXBZZBBNNTOV-UHFFFAOYSA-N 0.000 description 2
- 241000218378 Magnolia Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 241000949456 Zanthoxylum Species 0.000 description 2
- 206010000269 abscess Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000002925 dental caries Diseases 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 239000007888 film coating Substances 0.000 description 2
- 238000009501 film coating Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 235000021552 granulated sugar Nutrition 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- XWMMEBCFHUKHEX-MRTCRTFGSA-N (+)-Taraxasterol Chemical compound C([C@@]12C)C[C@H](O)C(C)(C)[C@@H]1CC[C@]1(C)[C@@H]2CC[C@H]2[C@@H]3[C@H](C)C(=C)CC[C@]3(C)CC[C@]21C XWMMEBCFHUKHEX-MRTCRTFGSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QMKPCZNFLUQTJZ-UHFFFAOYSA-N (4aR)-10c-Hydroxy-1t.2c.4ar.6at.6bc.9.9.12ac-octamethyl-(8atH.12btH.14acH.14btH)-docosahydro-picen Natural products CC1CCC2(C)CCC3(C)C(CCC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C QMKPCZNFLUQTJZ-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical class C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- QLDAACVSUMUMOR-UHFFFAOYSA-M 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride Chemical compound [Cl-].C1=C2C3=[N+](C)C=C4C=C(OC)C(OC)=CC4=C3C=CC2=CC2=C1OCO2 QLDAACVSUMUMOR-UHFFFAOYSA-M 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 235000007650 Aralia spinosa Nutrition 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- NRVMCZSNPIHCNL-QSNNAOSGSA-N C\C=C1/C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)OC=C2C1CC(=O)OCC1C(C)C(CC1C(C)CO)OC2=O Chemical compound C\C=C1/C(O[C@@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)OC=C2C1CC(=O)OCC1C(C)C(CC1C(C)CO)OC2=O NRVMCZSNPIHCNL-QSNNAOSGSA-N 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 235000009917 Crataegus X brevipes Nutrition 0.000 description 1
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 description 1
- 235000009685 Crataegus X maligna Nutrition 0.000 description 1
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 description 1
- 235000009486 Crataegus bullatus Nutrition 0.000 description 1
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 description 1
- 235000009682 Crataegus limnophila Nutrition 0.000 description 1
- 240000000171 Crataegus monogyna Species 0.000 description 1
- 235000004423 Crataegus monogyna Nutrition 0.000 description 1
- 235000002313 Crataegus paludosa Nutrition 0.000 description 1
- 235000009840 Crataegus x incaedua Nutrition 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010013911 Dysgeusia Diseases 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000058061 Glucose Transporter Type 4 Human genes 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 235000007457 Jasminum sambac Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 241000218377 Magnoliaceae Species 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 244000182216 Mimusops elengi Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 102000038030 PI3Ks Human genes 0.000 description 1
- 108091007960 PI3Ks Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 108091006300 SLC2A4 Proteins 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 1
- 241000292546 Taraxacum mongolicum Species 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010001093 acute tonsillitis Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000001760 anti-analgesic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000170 anti-cariogenic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 229940107681 dandelion root extract Drugs 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000002888 effect on disease Effects 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- XTLWNMXYCHABQH-UHFFFAOYSA-N germanicol Natural products CC1(C)CCC2(C)CCC3(C)C(CCC4(C)C5(C)CCC(O)C(C)(C)C5CCC34C)C2=C1 XTLWNMXYCHABQH-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- NRVMCZSNPIHCNL-UHFFFAOYSA-N jasminin Natural products O1C=C(C(OC2C(C)C(C(C2)C(C)CO)COC(=O)C2)=O)C2C(=CC)C1OC1OC(CO)C(O)C(O)C1O NRVMCZSNPIHCNL-UHFFFAOYSA-N 0.000 description 1
- KSMITTDZTTZFML-ZCFIWIBFSA-N jasminine Natural products O=C(OC)c1c2c([C@@H](C)NC(=O)C2)cnc1 KSMITTDZTTZFML-ZCFIWIBFSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- PKGKOZOYXQMJNG-UHFFFAOYSA-N lupeol Natural products CC(=C)C1CC2C(C)(CCC3C4(C)CCC5C(C)(C)C(O)CCC5(C)C4CCC23C)C1 PKGKOZOYXQMJNG-UHFFFAOYSA-N 0.000 description 1
- MQYXUWHLBZFQQO-QGTGJCAVSA-N lupeol Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C(=C)C)[C@@H]5[C@H]4CC[C@@H]3[C@]21C MQYXUWHLBZFQQO-QGTGJCAVSA-N 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 201000003265 lymphadenitis Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 230000033116 oxidation-reduction process Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 150000007965 phenolic acids Chemical class 0.000 description 1
- 235000013406 prebiotics Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- NGFFRJBGMSPDMS-UHFFFAOYSA-N psi-Taraxasterol Natural products CC12CCC(O)C(C)(C)C1CCC1(C)C2CCC2C3C(C)C(C)=CCC3(C)CCC21C NGFFRJBGMSPDMS-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- HUTYZQWCTWWXND-NCTFTGAASA-N taraxasterol Natural products C[C@H]1[C@H]2C3=CC[C@@H]4[C@@]5(C)CC[C@H](O)C(C)(C)[C@@H]5CC[C@@]4(C)[C@]3(C)C[C@H](O)[C@@]2(C)CCC1=C HUTYZQWCTWWXND-NCTFTGAASA-N 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/03—Organic compounds
- A23L29/035—Organic compounds containing oxygen as heteroatom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种茉莉花咀嚼片及其制备方法,该茉莉花咀嚼片包括以下重量百分比原料:茉莉花10‑15%,茉莉花茶2‑3%,两面针2‑3%,蒲公英2‑3%,黄芪2‑3%,厚朴酚0.01‑0.1%,糖粉18‑21%,麦芽糊精14‑16%,碳酸钙12‑14%,乳糖12‑14%,甘露醇13‑15%,柠檬酸0.5‑1.5%,阿斯巴甜0.5‑1.5%,硬脂酸镁0.5‑1.5%。本发明的茉莉花咀嚼片表面光滑美观,口感好风味佳,能持久散发茉莉花特有香味,具有清热解毒、改善心脑血管疾病、增强机体免疫力、抗病毒、抗肿瘤、抗龋防菌等功效。而且该茉莉花咀嚼片的制备方法简单,可进行工业化生产;采用本发明的方法制备茉莉花咀嚼片开发了茉莉花的新用途,经济效益好。
Description
技术领域
本发明属于保健食品技术领域,具体涉及一种茉莉花咀嚼片及其制备方法。
背景技术
茉莉花,别名:茉莉,拉丁文名:Jasminum sambac (L.) Ait,茉莉的花极香,为著名的花茶原料及重要的香精原料。茉莉花可提取茉莉花精油,精油中主要成分为苯甲醇及其酯类、茉莉花素、芳樟醇、安息香酸芳樟醇酯。茉莉花性寒,有清肝明目、通便利水、降低血压、理气安神之功效。现代医学研究表明,茉莉花所含成分具有很多药理作用:镇静、抗菌、抗氧化、改善糖尿病、防治抑郁、缓解胃肠道不适、护理口腔、保健心脑血管、提高免疫力等。
咀嚼片是指于口腔中咀嚼后吞服的片剂,因口感良好、服用方便而易于被患者接受。咀嚼片作为一种药物剂型具有其他剂型药物所无可比拟的优点:崩解时间较短、分散状态较好、药物溶出迅速、吸收速度快、生物利用度高、服用很方便,不受时间地点的限制,可以咀嚼,也可以吞服,同样可以含吮或用水分散后服用,进一步减少药物对胃肠道的刺激。此种剂型特别适合老人、小儿以及吞咽困难的患者服用。另外,有些苦味的片剂为了掩盖其苦味进行包衣,导致成品率低,而将其制成咀嚼片之后可以省去包衣的过程,缩短生产周期,进而提高成品率。咀嚼片的处方组成主要为药物与适宜辅料,咀嚼片常用辅料主要有几种:填充剂、黏合剂、润滑剂和矫味剂。填充剂主要用于填充片剂的质量和体积,从而便于压片,常用的填充剂有淀粉类、纤维素类、糖类和无机盐类等;黏合剂的主要作用是使药物粉末结合起来,常用的有蒸馏水、淀粉浆和乙醇等;润滑剂兼具助流、抗黏和润滑三种作用,常用的是硬脂酸镁、微粉硅胶和滑石粉等。其与普通片剂主要的区别在于:前者必需具有良好的口感,故其制备过程中矫味剂的选择尤为重要。常用的矫味剂有阿斯巴甜、乳糖、木糖醇等。咀嚼片经嚼碎后吞咽,没有崩解过程,所以不需要添加崩解剂。
专利申请CN101697810A公开了一种保健食品维生素C维生素E片及其生产方法,它是咀嚼片,由维生素C、维生素E、山梨醇、甘露醇、乳糖、柠檬酸、羟丙基甲基纤维素、二氧化硅、香精、硬脂酸镁、麦芽糊精、阿斯巴甜、铝色淀(一种是铝色淀包衣、一种是混料压有色片后包透明薄膜衣)、薄膜包衣料等原料按重量份配比组成。制备方法是:原料按重量份配比经粉碎、过筛、称取、混合、压片、包衣而成。本发明产品具有良好的抗氧化、防衰老、增强免疫力、维持机体正常代谢和功能等功效,是一种既美白防衰老又可提高人体免疫抗病能力的保健食品。专利CN106343548B公开了一种甘草黄酮复合蓝莓汁咀嚼片及其制备方法,甘草黄酮复合蓝莓汁咀嚼片,是按重量百分比由甘草黄酮浸膏、蓝莓汁、白砂糖、淀粉、麦芽糊精、柠檬酸、硬脂酸镁和甘露醇制成。制法:将白砂糖粉碎后加入淀粉、麦芽糊精,混合均匀后加入甘草黄酮浸膏和蓝莓汁,再搅拌均匀,得到软材,过筛,再将颗粒烘干,得到硬质颗粒;向硬质颗粒中加入柠檬酸、甘露醇,混合均匀,再加入硬脂酸镁,压片,得到甘草黄酮复合蓝莓汁咀嚼片。该咀嚼片具有抗氧化和抑菌作用,可用作保健品。专利CN103876142B公开了一种具有美容瘦身功效的超微粉咀嚼片,其由以下重量份的组分组成:山楂超微粉:30-60%,枸杞超微粉:5-10%,苹果超微粉:1-10%,玫瑰超微粉:1-10%,决明子超微粉:0.05-1%,荷叶超微粉:0.01-1%,甘露醇:1-20%,乳糖:10-50%,甜蜜素:0.1-1%,硬脂酸镁:0.2-1%。还公开了该超微粉咀嚼片的制备方法,包括超微粉制备、制粒、压片等步骤。本发明的具有美容瘦身功效的超微粉咀嚼片保持了物料原有的生物活性和营养成分,具有美容、瘦身、降脂、降压等功效,适合普通人群食用,特别适合女性及高血脂人群食用。
广西壮族自治区横县是全球茉莉花生产中心,茉莉花的产量和质量都居全中国之首。以前茉莉花一般被用来做成香包和枕头、窨制茶叶、制成饮料、提取茉莉花精油等,其中主要还是用来生产茉莉花茶,随着时代变革,茉莉花产量和成本的不断增加,以及市场竞争的加剧,深加工成高附加值的产品是茉莉花行业以后发展的必由之路。现已有少量人和企业对茉莉花的有效成分进行现代化提取纯化,再进一步加工成食品、药品、化妆品和保健品等附加值更高的产品了,但是至今还未有关于茉莉花咀嚼片的报道。而且,现有技术中,制备咀嚼片时,还存在裂片、松片、粘冲等问题。
发明内容
本发明的目的是提供一种茉莉花咀嚼片及其制备方法,该茉莉花咀嚼片表面光滑美观,口感好风味佳,能持久散发茉莉花特有香味,具有清热解毒、改善心脑血管疾病、增强机体免疫力、抗病毒、抗肿瘤、抗龋防菌等功效。而且该茉莉花咀嚼片的制备方法简单,可进行工业化生产;采用本发明的方法制备茉莉花咀嚼片开发了茉莉花的新用途,经济效益好。
本发明的技术方案如下:
一种茉莉花咀嚼片,包括以下重量百分比原料:茉莉花10-15%,茉莉花茶2-3%,两面针2-3%,蒲公英2-3%,黄芪2-3%,厚朴酚0.01-0.1%,糖粉18-21%,麦芽糊精14-16%,碳酸钙12-14%,乳糖12-14%,甘露醇13-15%,柠檬酸0.5-1.5%,阿斯巴甜0.5-1.5%,硬脂酸镁0.5-1.5%。
优选地,一种茉莉花咀嚼片,包括以下重量百分比原料:茉莉花12.62%,茉莉花茶2.52%,两面针2.52%,蒲公英2.52%,黄芪2.52%,厚朴酚0.05%,糖粉19.25%,麦芽糊精15%,碳酸钙13%,乳糖13%,甘露醇14%,柠檬酸1%,阿斯巴甜1%,硬脂酸镁1%。
所述茉莉花咀嚼片的制备方法,包括以下步骤:
(1)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪分别洗净晾干,然后经粉碎后过80目筛,得到的粉末按重量百分比加入到提取装置中,再加入5-15倍体积浓度为70-80%的乙醇进行加热回流提取1-3次,每次30-60min,得到茉莉花、茉莉花茶、两面针、蒲公英、黄芪的乙醇提取液。
(2)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪的混合乙醇提取液,与糖粉、麦芽糊精、碳酸钙、乳糖、甘露醇、柠檬酸、阿斯巴甜、厚朴酚按重量百分比混合均匀,在55℃下干燥至物料含水量为3%以下,然后经粉碎后过40-60目筛。
(3)向步骤(2)所得混合物缓慢、少量多次地喷洒质量浓度为2%的CMC-Na水溶液,同时不断进行搅拌,制成软材。
(4)将制得的软材挤压过20目的筛,使其分散成均匀、细粉较少的湿颗粒,把湿颗粒放置于烘干箱中,在55℃下干燥至物料含水量为3%以下,干燥期间翻动物料1-3次使其受热均匀。
(5)对干燥好的物料进行整理,使黏连的颗粒分散开来,得到大小均匀一致的颗粒,然后过20目筛,再加入硬脂酸镁,混匀后置于压片机进行压片。
所述茉莉花可以选用新鲜采摘的茉莉花,也可以选用给茶叶提香后的茉莉花。
所述厚朴酚采用CO2超临界萃取装置经以下步骤提取得到:
(1)厚朴药材用清水洗涤后,将其切成1-2cm厚的切片。
(2)将厚朴切片再次以去离子水洗涤后,粉碎至100-150目,再将厚朴粉放入萃取釜中装填。
(3)调节萃取釜的温度为318-338K、压强为6-22MPa,调节分离釜的温度为318-338K,开启CO2超临界提取装置的CO2气瓶,并加压。
(4)等加压到厚朴粉末与CO2形成混合流体后,静置0.5-1.5h。
(5)静置完毕后调节CO2流速为1-4L/h,开始动态萃取;0.5-1h后,萃取结束,开启装置出料即得厚朴提取物(浸膏状)。
(6)将厚朴提取物(浸膏状)用石油醚溶解静置12-24h;所得厚朴石油醚溶解液进行过滤,回收滤液。
(7)滤液用体积比为17:4-16的石油醚-乙酸乙酯混合液重结晶。
(8)所得结晶固体用乙醇洗涤后再加入乙酸乙酯中溶解,再次进行过滤,回收滤液。
(9)滤液再用体积比为17:1-4的石油醚-乙酸乙酯混合液重结晶;所得晶体即为厚朴酚(总酚)。采用CO2超临界萃取装置得到的厚朴酚得率为2.5-3.5%,纯度为92-95%。
关于本发明所用部分原料的介绍如下:
茉莉花茶是将茶叶和茉莉鲜花进行拼和、窨制,使茶叶吸收花香而成的茶叶;其香气鲜灵持久、滋味醇厚鲜爽、汤色黄绿明亮、叶底嫩匀柔软。经过一系列工艺流程窨制而成的茉莉花茶,具有安神、解抑郁、健脾理气、抗衰老、提高机体免疫力的功效,是一种健康饮品。茶叶中的茶多酚是一种天然抗氧化剂,具有抑制病毒活性、抗菌、抗诱变、治疗神经退行性疾病以及抗癌等作用,而且具有捕集机体内游离基、抗衰老、抗辐射、减肥、降血脂以及防癌等多方面的功效。此外,其对于免疫系统的疾病,特别是对艾滋病,也有良好的预防和治疗功效。现代医学研究表明,茶多糖是茶叶治疗糖尿病时的主要药理成分之一,茶多糖主要由葡萄糖、阿拉伯糖、木糖、岩藻糖、核糖、半乳糖等组成。茶多糖通过降血糖、降血脂,从而达到防治糖尿病的作用;同时在抗凝、防血栓形成,保护血相和增强人体非特异性免疫能力等方面均有明显效果。
两面针(学名:Zanthoxylum nitidum(Roxb.)DC.)是芸香科,花椒属木质藤本植物;以全草入药。两面针的根、茎、叶、果皮均用作草药,根性凉,果性温;有活血散瘀、行气止痛、祛风通络、解毒消肿等功效。民间用于跌打扭伤药,亦作驱蛔虫药。局部应用时,对神经末梢有麻醉作用,对胃痛或关节肌肉痛有缓解作用。根的水提液和酒精浸析液对溶血性链球菌和黄金色葡萄球菌均有显著抑制作用。现有研究报道阐明两面针中具有抗肿瘤作用的药效物质基础,即生物碱类,尤其以苯骈菲啶类、小蘖碱类、喹啉类三类的含量最多。氯化两面针碱可通过诱导细胞凋亡抑制人胃癌SGC-7901细胞增殖,通过降解MMP1和MMP2从而抑制SGC-7901细胞侵袭和迁移;通过多靶向降低表皮生长因子受体酪氨酸激酶(EGFR-TPK)活性、下调NF-κB的表达和激活Caspase 3活性的方式,对人鼻咽癌细胞的侵袭和增殖产生抑制作用;能明显抑制乳腺癌MCF-7细胞的增殖,其作用机制之一可能与上调p53表达水平、抑制P125表达有关;可通过调节肝癌SMMC-7721细胞POLD1基因的甲基化水平,影响其启动子转录调控因子的作用,从而抑制了POLD1基因表达,降低DNA聚合酶δ活性,抑制肝癌细胞增殖的作用。两面针活性成分能够诱导肝癌细胞凋亡,凋亡的肝癌细胞中核酸和蛋白质的含量均低于活细胞;且两面针活性成分作用时间与药效呈一定的相关性。两面针的抗炎、镇痛活性被广泛应用于治疗跌打损伤、胃痛、牙痛、风湿痹痛等方面。两面针总碱可降低胃液胃蛋白酶活性,使胃黏膜MDA含量降低,SOD活性和NO含量升高,从而起到抗溃疡作用。一定剂量的两面针总碱还具有明显的抗急性脑缺血作用。
蒲公英(拉丁学名:Taraxacum mongolicum Hand.-Mazz.)菊科,蒲公英属多年生草本植物。蒲公英植物体中含有蒲公英醇、蒲公英素、胆碱、有机酸、菊糖等多种健康营养成分。性味甘,微苦,寒。归肝、胃经。有清热解毒、消肿散结、抗菌消炎、利尿缓泻、保肝利胆、抗氧化、抗血栓、抗肿瘤、保护肠胃、提高免疫力、改善皮肤病等功效。用于治热毒、痈肿、疮疡、内痈、目赤肿痛、湿热、黄疸、小便淋沥涩痛、疔疮肿毒、乳痈、瘰疬、牙痛、目赤、咽痛、肺痈、肠痈、湿热黄疸、热淋涩痛。还可治急性乳腺炎,淋巴腺炎,急性结膜炎,感冒发热,急性扁桃体炎,急性支气管炎,胃炎,肝炎,胆囊炎,尿路感染等。现有研究发现,蒲公英中含有羽扇醇、多糖、黄酮、酚酸、三萜和植物甾醇等多种具有抗癌作用的化学成分。研究表明,蒲公英萜醇可通过mTOR信号通路诱导乳腺癌细胞自噬;蒲公英根提物能够降低MCF-7和HepG2细胞的细胞活性,对癌细胞的增殖有明显的抑制作用,能诱导癌细胞产生凋亡;蒲公英可抑制人肝癌SMMC-7721细胞增殖、黏附及运动。蒲公英多糖在平衡肠道微生物、增强免疫力、调控机体脂质代谢和氧化还原系统等方面发挥主要作用,可作为脂肪、糖的替代品以及益生元。蒲公英萜醇可通过PI3K通路有效地恢复地塞米松诱导的脱敏作用葡萄糖转运蛋白GLUT4表达并在逆转胰岛素抵抗中表现出显著的效果。
黄芪(学名:Astragalus membranaceus (Fisch.) Bunge.),又名绵芪,是豆科植物蒙古黄芪或荚膜黄芪的干燥根。性味:甘,微温。归经:归肺、脾、肝、肾经。黄芪具有补气升阳、固表止汗、利水消肿、生精养血、行滞通痹、脱毒排脓、敛疮生肌之功效。黄芪含有多种皂苷、黄酮、多糖以及氨基酸、亚油酸、生物碱、胆碱等复杂的化学成分。药理研究表明,黄芪具有增强机体免疫功能、强心、保肝、利尿、抗衰老、抗肿瘤、抗疲劳、抗病毒、抗应激、降压、降血糖和较广泛的抗菌作用。黄芪中的黄芪多糖成分,可有效提高机体巨噬细胞活性,改善T细胞及B细胞功能,增强机体免疫力,促进病情康复。黄芪进入人体后,有助于调节胰岛素分泌,减轻胰岛素抑制,降低血糖指标;提高肝脏内质网的应激作用,保护肝超微结构,增强肝功能。
中药材厚朴是木兰科植物厚朴(Magnolia officinalis Rehd. et Wils.)或凹叶厚朴(Magnolia officinalis subsp.biloba (Rehd. et Wils.) Cheng et Law)的干燥干皮、枝皮或者根皮,主要药用成分是厚朴酚。主要药理作用有:镇痛消炎、抗痉挛、抗溃疡。随着新的药效不断被发现,尤其是抗病毒、抗肿瘤以及抗龋防菌的药效,愈加受到人们的重视。
本发明的有益效果如下:
在本发明的的咀嚼片中,以茉莉花为主要原料,并添加了茉莉花茶、两面针、蒲公英、黄芪和厚朴,茉莉花及茉莉花茶均具有鲜灵持久的茉莉花香,可以起到清新口气的作用,同时也能掩盖药物的苦涩味;茉莉花茶还含有茶多酚、茶多糖等活性成分。以茉莉花、茉莉花茶、两面针、蒲公英、黄芪的乙醇热回流提取物入药,提取物中黄酮类、生物碱类、皂苷类、多糖等活性成分含量高,可以起到清热解毒、改善心脑血管疾病、增强机体免疫力、抗病毒、抗肿瘤等药效。另外,本发明的咀嚼片中还加入了厚朴酚,厚朴酚具有镇痛消炎、抗龋防菌的效果,可以增强咀嚼片的灭菌效果,起到改善口腔和肠胃问题的作用。
本发明的主要成分茉莉花可以选用新鲜采摘的茉莉花,也可以选用给茶叶提香后的茉莉花。茉莉鲜花在给茶叶提香后所余下的半枯萎花朵,除了香味成分有所损失,其大部分营养物质和大部分药理活性成分例如茉莉花脂肪类、蛋白质、多糖、黄酮和生物碱都还在,为了不浪费茉莉花,将其制备成茉莉花咀嚼片,能进一步发挥其剩余成分的作用,提高茉莉花的利用率。厚朴酚采用CO2超临界萃取装置提取得到,厚朴酚得率高,纯度好。
本发明的茉莉花咀嚼片在选择辅料时,针对现有咀嚼片中存在的主要问题:裂片、松片、粘冲等对常用的部分辅料进行了正交试验,最终选定了本发明所述的辅料并设定了较优的配比。填充剂为甘露醇、乳糖两者复配使用,因其性质更满足咀嚼片口感、硬度等方面的要求。
麦芽糊精具有低热量的特点,价格也低廉,口感比糊精好。糖粉可用来增加片剂的硬度,能使其表面美观、光滑,还可充当矫味剂的角色。乳糖可压性良好,性质也稳定,味微甜。药用碳酸钙性质稳定,无臭无味,制成的片剂光洁,还可增加片剂硬度。甘露醇味甜,无吸湿性,溶解时吸热会带来凉爽感。阿斯巴甜的甜度约为蔗糖的200倍,味、质近似于蔗糖,无不良后味,其不仅可以降低产品的热量、预防龋齿,还对苦味有较好的掩盖作用。柠檬酸具有增加风味、抑制细菌等作用。硬脂酸镁易与物料混匀,成片后片面光滑美观。采用本发明的辅料与药用原料搭配压制得到的咀嚼片,片面光滑美观、口感好,硬度适宜,裂片率和松片率低。
附图说明
图1是本发明的茉莉花咀嚼片样品。
具体实施方式
为了更加详细的介绍本发明,下面结合实施例,对本发明做进一步说明。
实施例1
一种茉莉花咀嚼片,包括以下重量百分比原料:茉莉花12.62%,茉莉花茶2.52%,两面针2.52%,蒲公英2.52%,黄芪2.52%,厚朴酚0.05%,糖粉19.25%,麦芽糊精15%,碳酸钙13%,乳糖13%,甘露醇14%,柠檬酸1%,阿斯巴甜1%,硬脂酸镁1%。
所述茉莉花咀嚼片的制备方法,包括以下步骤:
(1)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪分别洗净晾干,然后经粉碎后过80目筛,得到的粉末按重量百分比加入到提取装置中,再加入10倍体积浓度为75%的乙醇进行加热回流提取2次,每次45min,得到茉莉花、茉莉花茶、两面针、蒲公英、黄芪的乙醇提取液。
(2)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪的混合乙醇提取液,与糖粉、麦芽糊精、碳酸钙、乳糖、甘露醇、柠檬酸、阿斯巴甜、厚朴酚按重量百分比混合均匀,在55℃下真空干燥至物料含水量为3%以下,然后经粉碎后过50目筛。
(3)向步骤(2)所得混合物缓慢、少量多次地喷洒质量浓度为2%的CMC-Na水溶液,同时不断进行搅拌,制成“手握成团,轻压即散”状态的软材。
(4)将制得的软材挤压过20目的筛,使其分散成均匀、细粉较少的湿颗粒,把湿颗粒放置于真空烘干箱中,在55℃下真空干燥至物料含水量为3%以下,干燥期间翻动物料2次使其受热均匀。
(5)对干燥好的物料进行整理,使黏连的颗粒分散开来,得到大小均匀一致的颗粒,然后过20目筛,再加入硬脂酸镁,混匀后置于压片机进行压片。
所述茉莉花选用广西横县新鲜采摘的茉莉花,所述茉莉花茶选用由老树的叶子经广西横县的茉莉花窨制后制得的茶叶。
所述厚朴酚采用CO2超临界萃取装置经以下步骤提取得到:
(1)厚朴药材用清水洗涤后,将其切成1-2cm厚的切片。
(2)将厚朴切片再次以去离子水洗涤后,粉碎至120目,再将厚朴粉放入萃取釜中装填。
(3)调节萃取釜的温度为318-338K、压强为6-22MPa,调节分离釜的温度为318-338K,开启CO2超临界提取装置的CO2气瓶,并加压。
(4)等加压到厚朴粉末与CO2形成混合流体后,静置1h。
(5)静置完毕后调节CO2流速为2L/h,开始动态萃取;45min后,萃取结束,开启装置出料即得厚朴提取物(浸膏状)。
(6)将厚朴提取物(浸膏状)用石油醚溶解静置18h;所得厚朴石油醚溶解液用真空过滤机过滤,回收滤液。
(7)滤液用体积比为17:10的石油醚-乙酸乙酯混合液重结晶。
(8)所得结晶固体用乙醇洗涤后再加入乙酸乙酯中溶解,再次用真空过滤机过滤,回收滤液。
(9)滤液再用体积比为17:2的石油醚-乙酸乙酯混合液重结晶;所得晶体即为厚朴酚(总酚)。
实施例2
一种茉莉花咀嚼片,包括以下重量百分比原料:茉莉花10%,茉莉花茶2%,两面针2%,蒲公英2%,黄芪2%,厚朴酚0.1%,糖粉21%,麦芽糊精15%,碳酸钙14%,乳糖12.5%,甘露醇15%,柠檬酸1.5%,阿斯巴甜1.4%,硬脂酸镁1.5%。
(1)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪分别洗净晾干,然后经粉碎后过80目筛,得到的粉末按重量百分比加入到提取装置中,再加入5倍体积浓度为80%的乙醇进行加热回流提取60min,得到茉莉花、茉莉花茶、两面针、蒲公英、黄芪的乙醇提取液。
(2)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪的混合乙醇提取液,与糖粉、麦芽糊精、碳酸钙、乳糖、甘露醇、柠檬酸、阿斯巴甜、厚朴酚按重量百分比混合均匀,在55℃下真空干燥至物料含水量为3%以下,然后经粉碎后过40目筛。
(3)向步骤(2)所得混合物缓慢、少量多次地喷洒质量浓度为2%的CMC-Na水溶液,同时不断进行搅拌,制成“手握成团,轻压即散”状态的软材。
(4)将制得的软材挤压过20目的筛,使其分散成均匀、细粉较少的湿颗粒,把湿颗粒放置于真空烘干箱中,在55℃下真空干燥至物料含水量为3%以下,干燥期间翻动物料1次使其受热均匀。
(5)对干燥好的物料进行整理,使黏连的颗粒分散开来,得到大小均匀一致的颗粒,然后过20目筛,再加入硬脂酸镁,混匀后置于压片机进行压片。
所述茉莉花茶选用由老树的叶子经广西横县的茉莉花窨制后制得的茶叶,所述茉莉花选用给茶叶提香后的广西横县茉莉花。
所述厚朴酚采用CO2超临界萃取装置经以下步骤提取得到:
(1)厚朴药材用清水洗涤后,将其切成1-2cm厚的切片。
(2)将厚朴切片再次以去离子水洗涤后,粉碎至100目,再将厚朴粉放入萃取釜中装填。
(3)调节萃取釜的温度为318-338K、压强为6-22MPa,调节分离釜的温度为318-338K,开启CO2超临界提取装置的CO2气瓶,并加压。
(4)等加压到厚朴粉末与CO2形成混合流体后,静置1.5h。
(5)静置完毕后调节CO2流速为4L/h,开始动态萃取;0.5h后,萃取结束,开启装置出料即得厚朴提取物(浸膏状)。
(6)将厚朴提取物(浸膏状)用石油醚溶解静置12h;所得厚朴石油醚溶解液用真空过滤机过滤,回收滤液。
(7)滤液用体积比为17:16的石油醚-乙酸乙酯混合液重结晶。
(8)所得结晶固体用乙醇洗涤后再加入乙酸乙酯中溶解,再次用真空过滤机过滤,回收滤液。
(9)滤液再用体积比为17:1的石油醚-乙酸乙酯混合液重结晶;所得晶体即为厚朴酚(总酚)。
实施例3
一种茉莉花咀嚼片,包括以下重量百分比原料:茉莉花15%,茉莉花茶3%,两面针3%,蒲公英3%,黄芪3%,厚朴酚0.01%,糖粉20.25%,麦芽糊精14%,碳酸钙12%,乳糖12%,甘露醇13.24%,柠檬酸0.5%,阿斯巴甜0.5%,硬脂酸镁0.5%。
所述茉莉花咀嚼片的制备方法,包括以下步骤:
(1)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪分别洗净晾干,然后经粉碎后过80目筛,得到的粉末按重量百分比加入到提取装置中,再加入15倍体积浓度为70%的乙醇进行加热回流提取3次,每次30min,得到茉莉花、茉莉花茶、两面针、蒲公英、黄芪的乙醇提取液。
(2)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪的混合乙醇提取液,与糖粉、麦芽糊精、碳酸钙、乳糖、甘露醇、柠檬酸、阿斯巴甜、厚朴酚按重量百分比混合均匀,在55℃下真空干燥至物料含水量为3%以下,然后经粉碎后过60目筛。
(3)向步骤(2)所得混合物缓慢、少量多次地喷洒质量浓度为2%的CMC-Na水溶液,同时不断进行搅拌,制成“手握成团,轻压即散”状态的软材。
(4)将制得的软材挤压过20目的筛,使其分散成均匀、细粉较少的湿颗粒,把湿颗粒放置于真空烘干箱中,在55℃下真空干燥至物料含水量为3%以下,干燥期间翻动物料3次使其受热均匀。
(5)对干燥好的物料进行整理,使黏连的颗粒分散开来,得到大小均匀一致的颗粒,然后过20目筛,再加入硬脂酸镁,混匀后置于压片机进行压片。
所述茉莉花茶选用由老树的叶子经广西横县的茉莉花窨制后制得的茶叶,所述茉莉花选用给茶叶提香后的广西横县茉莉花。
所述厚朴酚采用CO2超临界萃取装置经以下步骤提取得到:
(1)厚朴药材用清水洗涤后,将其切成1-2cm厚的切片。
(2)将厚朴切片再次以去离子水洗涤后,粉碎至150目,再将厚朴粉放入萃取釜中装填。
(3)调节萃取釜的温度为318-338K、压强为6-22MPa,调节分离釜的温度为318-338K,开启CO2超临界提取装置的CO2气瓶,并加压。
(4)等加压到厚朴粉末与CO2形成混合流体后,静置0.5h。
(5)静置完毕后调节CO2流速为1L/h,开始动态萃取;1h后,萃取结束,开启装置出料即得厚朴提取物(浸膏状)。
(6)将厚朴提取物(浸膏状)用石油醚溶解静置24h;所得厚朴石油醚溶解液用真空过滤机过滤,回收滤液。
(7)滤液用体积比为17:4的石油醚-乙酸乙酯混合液重结晶。
(8)所得结晶固体用乙醇洗涤后再加入乙酸乙酯中溶解,再次用真空过滤机过滤,回收滤液。
(9)滤液再用体积比为17:4的石油醚-乙酸乙酯混合液重结晶;所得晶体即为厚朴酚(总酚)。
采用本发明实施例1的制备方法制备得到的茉莉花咀嚼片样品见图1。为了验证本发明的茉莉花咀嚼片的灭菌效果,本发明还对实施例1制备得到的产品以及本申请人前期研究的产品(相较于本发明实施例1的产品仅缺少厚朴酚)进行了灭菌试验,相关实验和结果判定标准均按照中华人民共和国1996年版《公共场所空气卫生细菌学标准》所述具体操作和规定执行。结果见下表1。
可见,增加厚朴酚可以增强咀嚼片的灭菌效果,由本发明的制备方法制备得到的咀嚼片具有很强的灭菌效果,可以改善因细菌引起的口腔和肠胃问题。
Claims (5)
1.一种茉莉花咀嚼片,其特征在于,所述茉莉花咀嚼片包括以下重量百分比原料:茉莉花10-15%,茉莉花茶2-3%,两面针2-3%,蒲公英2-3%,黄芪2-3%,厚朴酚0.01-0.1%,糖粉18-21%,麦芽糊精14-16%,碳酸钙12-14%,乳糖12-14%,甘露醇13-15%,柠檬酸0.5-1.5%,阿斯巴甜0.5-1.5%,硬脂酸镁0.5-1.5%。
2.根据权利要求1所述茉莉花咀嚼片,其特征在于,所述茉莉花咀嚼片包括以下重量百分比原料:茉莉花12.62%,茉莉花茶2.52%,两面针2.52%,蒲公英2.52%,黄芪2.52%,厚朴酚0.05%,糖粉19.25%,麦芽糊精15%,碳酸钙13%,乳糖13%,甘露醇14%,柠檬酸1%,阿斯巴甜1%,硬脂酸镁1%。
3.根据权利要求1所述茉莉花咀嚼片,其特征在于,所述茉莉花咀嚼片的制备方法,包括以下步骤:
(1)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪分别洗净晾干,然后经粉碎后过80目筛,得到的粉末按重量百分比加入到提取装置中,再加入5-15倍体积浓度为70-80%的乙醇进行加热回流提取1-3次,每次30-60min,得到茉莉花、茉莉花茶、两面针、蒲公英、黄芪的乙醇提取液;
(2)将茉莉花、茉莉花茶、两面针、蒲公英、黄芪的混合乙醇提取液,与糖粉、麦芽糊精、碳酸钙、乳糖、甘露醇、柠檬酸、阿斯巴甜、厚朴酚按重量百分比混合均匀,在55℃下干燥至物料含水量为3%以下,然后经粉碎后过40-60目筛;
(3)向步骤(2)所得混合物缓慢、少量多次地喷洒质量浓度为2%的CMC-Na水溶液,同时不断进行搅拌,制成软材;
(4)将制得的软材挤压过20目的筛,使其分散成均匀、细粉较少的湿颗粒,把湿颗粒放置于烘干箱中,在55℃下干燥至物料含水量为3%以下,干燥期间翻动物料1-3次使其受热均匀;
(5)对干燥好的物料进行整理,使黏连的颗粒分散开来,得到大小均匀一致的颗粒,然后过20目筛,再加入硬脂酸镁,混匀后置于压片机进行压片。
4.根据权利要求1-3任一项所述茉莉花咀嚼片,其特征在于,所述茉莉花可以选用新鲜采摘的茉莉花,也可以选用给茶叶提香后的茉莉花。
5.根据权利要求1-3任一项所述茉莉花咀嚼片,其特征在于,所述厚朴酚是采用CO2超临界萃取装置提取得到的,具体提取步骤如下:
(1)厚朴药材用清水洗涤后,将其切成1-2cm厚的切片;
(2)将厚朴切片再次以去离子水洗涤后,粉碎至100-150目,再将厚朴粉放入萃取釜中装填;
(3)调节萃取釜的温度为318-338K、压强为6-22MPa,调节分离釜的温度为318-338K,开启CO2超临界提取装置的CO2气瓶,并加压;
(4)等加压到厚朴粉末与CO2形成混合流体后,静置0.5-1.5h;
(5)静置完毕后调节CO2流速为1-4L/h,开始动态萃取;0.5-1h后,萃取结束,开启装置出料即得厚朴提取物;
(6)将厚朴提取物用石油醚溶解静置12-24h;所得厚朴石油醚溶解液进行过滤,回收滤液;
(7)滤液用体积比为17:4-16的石油醚-乙酸乙酯混合液重结晶;
(8)所得结晶固体用乙醇洗涤后再加入乙酸乙酯中溶解,再次进行过滤,回收滤液;
(9)滤液再用体积比为17:1-4的石油醚-乙酸乙酯混合液重结晶;所得晶体即为厚朴酚。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010468362.9A CN111567804A (zh) | 2020-05-28 | 2020-05-28 | 茉莉花咀嚼片及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010468362.9A CN111567804A (zh) | 2020-05-28 | 2020-05-28 | 茉莉花咀嚼片及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111567804A true CN111567804A (zh) | 2020-08-25 |
Family
ID=72114205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010468362.9A Pending CN111567804A (zh) | 2020-05-28 | 2020-05-28 | 茉莉花咀嚼片及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111567804A (zh) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1698667A (zh) * | 2004-05-18 | 2005-11-23 | 安徽科创中药天然药物研究所有限责任公司 | 黄芪提取物咀嚼片及黄芪提取物的制备方法 |
CN101544543A (zh) * | 2008-03-28 | 2009-09-30 | 广州合诚三先生物科技有限公司 | 厚朴药材中酚类化合物的纯化分离方法 |
CN105614426A (zh) * | 2014-10-27 | 2016-06-01 | 卢雨萍 | 一种茉莉花咀嚼片及其制作方法 |
CN106176901A (zh) * | 2016-08-25 | 2016-12-07 | 刘根喜 | 一种黄芪咀嚼片及其制备方法 |
CN109527564A (zh) * | 2018-12-29 | 2019-03-29 | 宁夏润丰枸杞生物制品有限公司 | 枸杞黄芪咀嚼片及其制备方法 |
-
2020
- 2020-05-28 CN CN202010468362.9A patent/CN111567804A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1698667A (zh) * | 2004-05-18 | 2005-11-23 | 安徽科创中药天然药物研究所有限责任公司 | 黄芪提取物咀嚼片及黄芪提取物的制备方法 |
CN101544543A (zh) * | 2008-03-28 | 2009-09-30 | 广州合诚三先生物科技有限公司 | 厚朴药材中酚类化合物的纯化分离方法 |
CN105614426A (zh) * | 2014-10-27 | 2016-06-01 | 卢雨萍 | 一种茉莉花咀嚼片及其制作方法 |
CN106176901A (zh) * | 2016-08-25 | 2016-12-07 | 刘根喜 | 一种黄芪咀嚼片及其制备方法 |
CN109527564A (zh) * | 2018-12-29 | 2019-03-29 | 宁夏润丰枸杞生物制品有限公司 | 枸杞黄芪咀嚼片及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102784363B (zh) | 一种治疗胰腺癌的中药组合物及其制备方法 | |
CN103893252A (zh) | 具有清咽利喉作用的组合物及其制备方法和应用 | |
CN103893722B (zh) | 一种治疗日光性皮炎的中药组合物及其制备方法 | |
CN107029146A (zh) | 一种清肺化痰补气健脾养肺的中药组合物及其制备方法 | |
CN103168883A (zh) | 可增强免疫力、抗病原微生物、抗病毒的茶饮料颗粒剂及其制备方法 | |
JP2003192605A (ja) | リパーゼ阻害剤 | |
CN108813501B (zh) | 具有清热润肺止咳化痰平喘和调节人体机能的养生蜂蜜膏 | |
CN104274763A (zh) | 治疗外感时毒型复发性口腔溃疡的中药制剂及其制备方法 | |
CN105288597B (zh) | 一种治疗皮肤色素沉着的药物 | |
CN104547515A (zh) | 一种橘红梨膏及其制备方法 | |
CN107114781B (zh) | 一种用于保肝的保健食品及其制备方法 | |
CN111567797A (zh) | 复方茉莉花茶咀嚼片及其制备方法 | |
CN101254263A (zh) | 复方瓜子金口服液及其制备方法 | |
CN1238007C (zh) | 金银灵芝茶及其制备方法 | |
CN110151851A (zh) | 一种以金银花甘草药对为基础的复合物及其应用 | |
CN108969591A (zh) | 一种净化血液的制剂 | |
CN108310156A (zh) | 一种治疗儿科腹泻的中药组合物及其制备方法 | |
CN103960415A (zh) | 一种减肥保健凉茶及其制备方法 | |
EP1968401B1 (en) | Functional food composition for treating allergy, natural tea using the same and the manufacturing method thereof | |
CN103845616A (zh) | 一种消炎杀菌的药物组合物 | |
CN103623120A (zh) | 一种清咽利喉含片及其制备方法 | |
CN111567804A (zh) | 茉莉花咀嚼片及其制备方法 | |
CN104352866A (zh) | 一种治疗火毒伤津型烧伤的中药制剂及其制备方法 | |
CN105343840A (zh) | 一种中医内科治疗肺炎的中药 | |
CN105617268A (zh) | 一种治疗鳞屑角化型脚气的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200825 |
|
RJ01 | Rejection of invention patent application after publication |